Cancer Imaging Program and Research

The Cancer Imaging Program brings together expertise in clinical and basic research imaging, and their goal is to improve the identification, diagnosis, and treatment of tumors. Investigators are from the Department of Radiology and the Department of Neurology, with collaborations with other Cancer Research programs.


  • Development of procedures guidelines to assist physicians in recommending, performing, interpreting, and reporting the results of various imaging modalities for imaging of adult and pediatric patients
  • The use of advanced tumor perfusion imaging techniques to differentiate treatment effects from recurrrent/progressive tumors
  • The use of MRI and CT data, patient charts, histopathology and TCGA /REMBRANDT genomic data to identify surrogate imaging biomarkers that correlate with gene expression
  • Differentiating glioma tissue from radiation injury
  • Cell-mediated gene therapy using stem cells to deliver suicide genes to the sites of glioma and breast cancer in animal models
  • Determining the changes in tumor vascular permeability following therapy targeting EGFR and VEGFR2 utilizing Gd-albumin and iron oxides nanoparticles
  • Characterization of different stem cell populations collected from cord blood and bone marrow
  • Utilization of molecular imaging facilities (optical imaging) to track the migration and accumulation of genetically modified cells to sites of interest
  • Optical imaging to track the migration and accumulation of nanoprobes to specific targets in brain tumors
  • Develop noninvasive unbiased estimates of cerebrovascular physiological parameters, including cerebral blood flow, cerebral blood volume, the transvascular transfer constant, and related parameters as extracellular volume fraction, interstitial fluid pressure, and interstitial volume fraction as indicators for therapeutic response
  • Developing specialized MRI sequences and post-processing software
  • Developing chemical synthesis methods to create biomedical imaging agents from bifunctional macrocyclic ligands that tightly bind to Gd3+ and other lanthanide metals (Eu3+,Tm3+, Yb3+)
  • MRI to study tumor progression and the early responses to chemotherapies in pre-clinical models of breast and brain tumors
  • Development of multifunctional dendritic MRI contrast agents that will target multiple cancer biomarkers that are specific to tumor microenvironment

See member profiles for comprehensive research interests

Leader and clinical co-leader

  • Ewing, James, Ph.D.
  • Patel, Suresh, M.D.

Research members

  • Ali, Mesera, PH.D.
  • Arbab, Ali, S., M.D., Ph.D.
  • Bagher-Ebadian, Hassan, PH.D.
  • Ewing, James, Ph.D.
  • Knight, Robert, PH.D.
  • Nagaraja, Tavarekere PH.D.

Clinical members

  • Aho Todd, M.D.
  • Brown, Mani, M.D.
  • Bonnett, John, M.D.
  • Miller, Patricia, M.D.
  • Park, Hakim, M.D.
  • Spizarny, David, M.D.